{"id":129903,"date":"2018-07-12T06:45:26","date_gmt":"2018-07-12T10:45:26","guid":{"rendered":"https:\/\/www.countingpips.com\/?p=129903"},"modified":"2018-07-11T21:00:36","modified_gmt":"2018-07-12T01:00:36","slug":"preclinical-data-for-alzheimers-therapy-to-be-presented-at-aaic","status":"publish","type":"post","link":"https:\/\/www.investmacro.com\/forex\/2018\/07\/preclinical-data-for-alzheimers-therapy-to-be-presented-at-aaic\/","title":{"rendered":"Preclinical Data for Alzheimer’s Therapy to Be Presented at AAIC"},"content":{"rendered":"
July 12, 2018<\/div>
\r\n<\/div><\/div>

By The Life Science Report<\/b><\/p>\n

Source: Streetwise Reports<\/em> \u00a0\u00a007\/11\/2018<\/a><\/b><\/p>\n

A poster outlining data from this company’s lead candidate, which targets toxic oligomers identified as a potential cause of Alzheimer’s disease, will be presented at the Alzheimer’s Association International Conference (AAIC).<\/p><\/blockquote>\n

In a July 10 press release<\/a>, ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB)<\/a> announced it would be presenting preclinical data regarding PMN310 at the AAIC, to be held in Chicago beginning on July 22.<\/p>\n

The company, which is focused on “discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases,” will present a poster titled “Humanized PMN310 shows enhanced therapeutic potential by binding toxic low molecular weight A\u03b2 oligomers while avoiding ARIA-related binding to A\u03b2 deposits in AD patient brains.”<\/p>\n

In the announcement, ProMIS chief development officer Johanne Kaplan stated that PMN310 “may provide greater therapeutic potency and safety compared to other A\u03b2-directed antibodies due to its selective targeting of soluble toxic oligomers and the consequently reduced risk of amyloid related imaging abnormalities, or ARIA, allowing for safe administration of higher doses of antibody.”<\/p>\n

According to the company, the processes leading to development of Alzheimer’s disease may not stem from plaques, but rather from toxic amyloid beta (A\u03b2) oligomers. PMN310, according to ProMIS president and CEO Dr. Elliot Goldstein, “selectively target[s] and neutralize[s] toxic A\u03b2 oligomers with no significant off-target binding to A\u03b2 monomers or plaque.”<\/p>

\r\n
\r\n

Free Reports:<\/p><\/div>\r\n

\r\n

<\/a>\r\n\t Get Our Free Metatrader 4 Indicators<\/u><\/b><\/a> - Put Our Free MetaTrader 4 Custom Indicators on your charts when you join our Weekly Newsletter<\/p>

\r\n
\r\n
\r\n

<\/a>\r\n\t Get our Weekly Commitment of Traders Reports<\/u><\/b><\/a> - See where the biggest traders (Hedge Funds and Commercial Hedgers) are positioned in the futures markets on a weekly basis.<\/p>

\r\n<\/div>\r\n

\r\n
<\/div>\n

In the release, Dr. Goldstein expressed the company’s belief that “the particular, oligomer selective profile of PMN310 supports a potential best in class profile compared to [other] A\u03b2 therapeutic antibodies currently showing promising results in clinical trials.”<\/p>\n

The company plans to begin clinical trials for PMN310 in the second half of 2019.<\/p>\n

\n

Read what other experts are saying about:<\/p>\n